Last $13.46 USD
Change Today +0.31 / 2.36%
Volume 502.9K
OSIR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

osiris therapeutics inc (OSIR) Snapshot

Open
$13.20
Previous Close
$13.15
Day High
$13.51
Day Low
$13.04
52 Week High
10/4/13 - $19.75
52 Week Low
04/21/14 - $11.80
Market Cap
461.8M
Average Volume 10 Days
166.1K
EPS TTM
$0.04
Shares Outstanding
34.3M
EX-Date
--
P/E TM
327.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for OSIRIS THERAPEUTICS INC (OSIR)

osiris therapeutics inc (OSIR) Related Businessweek News

No Related Businessweek News Found

osiris therapeutics inc (OSIR) Details

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing products to treat medical conditions in wound care, orthopedic, and sports medicine markets. The company’s stem cell drug, remestemcel-L, is indicated for graft versus host disease. Its products include Grafix and Ovation for acute and chronic wounds; Cartiform, a viable cartilage mesh for cartilage repair; and OvationOS, a viable bone matrix. It markets and distributes its products directly to hospitals and clinics, as well as through a network of distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

70 Employees
Last Reported Date: 03/31/14
Founded in 1992

osiris therapeutics inc (OSIR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.8K
Chief Financial Officer, Treasurer and Corpor...
Total Annual Compensation: $227.3K
Compensation as of Fiscal Year 2013.

osiris therapeutics inc (OSIR) Key Developments

Osiris Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Osiris Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $66,000, loss from continuing operations before income taxes of before income taxes of $1,298,000 and net loss of $1,885,000 or $0.05 per diluted share on product revenues of $13,290,000 against loss from operations of $1,480,000, loss from continuing operations before income taxes of $1,455,000 and net loss of $3,756,000 or $0.06 per diluted share on product revenues of $5,291,000 for the same period a year ago. Loss from continuing operations was $1,428,000 or $0.04 per basic and diluted share compared to $1,813,000 or $0.05 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $681,000, loss from continuing operations before income taxes of before income taxes of $2,039,000 and net loss of $3,250,000 or $0.09 per basic and diluted share on product revenues of $23,344,000 against loss from operations of $2,162,000, loss from continuing operations before income taxes of $2,108,000 and net loss of $6,491,000 or $0.19 per basic and diluted share on product revenues of $9,346,000 for the same period a year ago. Loss from continuing operations was $2,039,000 or $0.09 per basic and diluted share compared to $2,108,000 or $0.19 per basic and diluted share a year ago.

Osiris Therapeutics, Inc. Expands its Grafix Product Portfolio and Launches Additional Sizes

Osiris Therapeutics, Inc. announced the addition of several new sizes to the Grafix product line. Grafix, a cryopreserved placental membrane, is regulated under 21 CFR 1271, part 361, Human Cells, Tissues and Cellular Tissue-Products (HCT/Ps) as a wound cover. Like other HCT/Ps, Grafix can be manufactured in multiple sizes, giving health care providers the ability to optimally match Grafix to the wound size, reduce overall treatment costs and eliminate concerns regarding product waste. Grafix is now available in five convenient sizes and is very well-positioned to remain a cost effective option within the Centers for Medicare & Medicaid Services bundled payment system. In addition to the launch of multiple new sizes, Osiris is introducing an innovative delivery system. The new design reduces thaw time, increases product maneuverability and eases the overall application of Grafix to the wound bed.

Osiris Therapeutics, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Osiris Therapeutics, Inc. announced that they will report Q2, 2014 results at 1:00 PM, GMT Standard Time on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $13.46 USD +0.31

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bionet Corp 43.30 TWD +0.70
BioTime Inc $3.79 USD +0.24
Cryo-Cell International Inc $3.25 USD -0.012
Organovo Holdings Inc $6.57 USD -0.42
Vitrolife AB kr133.00 SEK +3.00
View Industry Companies
 

Industry Analysis

OSIR

Industry Average

Valuation OSIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.8x
Price/Book 5.6x
Price/Cash Flow 10.1x
TEV/Sales 10.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit www.osiristx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.